Investigating the effect of mesenchymal stem cells on airway hyper-responsiveness in asthma

Asthma is a lung disease characterized by eosinophilic inflammation, mucus secretion, airway hyper-responsiveness (AHR), and airway obstruction. AHR is a crucial factor in asthma. Mesenchymal stem cells (MSCs) have a regulatory effect on the immune response and may be useful in treating asthma. MSCs have low immunogenicity and are considered safe for application. Additionally, a study was conducted to investigate the effect of MSCs on controlling AHR in an asthma model. MSCs were isolated and used to treat asthmatic male BALB/c mice. To produce an animal model of asthma, the mice were sensitized and challenged with OVA. On days 30 and 40, to measure AHR, a Methacholine challenge test was performed to determine the Penh value. AHR was recorded and analyzed. Treatment of asthmatic mice with MSCs resulted in a significant difference (p<0.05) in controlling AHR during the MCh challenge test. MSCs are almost non-immunogenic and can be used to treat asthma and control AHR. The use of MSCs as an anti-asthma treatment presents a new and applicable strategy for controlling AHR in asthma.